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Whether signals mediated via growth factor recep-
tors (GFRs) might influence lineage fate in multipo-
tent progenitors (MPPs) is unclear. We explored
this issue in a mouse knockin model of gain-of-
function Flt3-ITD mutation because FLT3-ITDs are
paradoxically restricted to acute myeloid leukemia
even though Flt3 primarily promotes lymphoid devel-
opment during normal hematopoiesis. When ex-
pressed in MPPs, Flt3-ITD collaborated with Runx1
mutation to induce high-penetrance aggressive
leukemias that were exclusively of the myeloid
phenotype. Flt3-ITDs preferentially expanded MPPs
with reduced lymphoid and increased myeloid tran-
scriptional priming while compromising early B and
T lymphopoiesis. Flt3-ITD-induced myeloid lineage
bias involved upregulation of the transcription factor
Pu.1, which is a direct target gene of Stat3, an
aberrantly activated target of Flt3-ITDs, further
establishing how lineage bias can be inflicted on
MPPs through aberrant GFR signaling. Collectively,
these findings provide new insights into how onco-
genic mutations might subvert the normal process
of lineage commitment and dictate the phenotype
of resulting malignancies.INTRODUCTION
Whether signals mediated via growth factor receptors (GFRs)
might influence lineage fate in normal multipotent progenitors
(MPPs) and stem cells remains unclear and disputed. New in-1766 Cell Reports 3, 1766–1776, June 27, 2013 ª2013 The Authorssights into this process have recently been gained through
studies in vitro (Rieger et al., 2009); however, whether GFR
signaling instructs lineage specification in vivo remains a key un-
resolved issue (Enver and Jacobsen, 2009). Studying the impact
of gain-of-functionmutations is an alternative approach to deter-
mine whether and how GFRs might instruct lineage fate in vivo.
Indeed, activating mutations of GFRs and downstream signaling
pathways are common events in cancer, particularly in hemato-
poietic malignancies such as acute myeloid leukemia (AML), and
often show striking associations with distinct clinical and cell-
lineage phenotypes (Croce, 2008). In some cases, this might
simply reflect the fact that such mutations primarily target a spe-
cific cell lineage. However, more intriguingly, if amutation targets
a primitive multipotent cell, it might instruct lineage-fate deci-
sions. As recent investigations of human AML have suggested
that the propagating cell might frequently represent the counter-
part of normal MPPs (Goardon et al., 2011), it is possible but still
unclear to what degree GFR signaling mutations might also influ-
ence lineage specification in multipotent cells.
A good example of aberrant GFR signaling associated with
specific leukemia phenotypes relates to the FMS-like tyrosine
kinase 3 receptor (FLT3), which is expressed in the majority of
cases of AML and acute lymphoblastic leukemia (ALL) (Stirewalt
and Radich, 2003). Constitutively activating internal tandem
duplications (ITDs) within the juxtamembrane domain of FLT3
occur in 25% of cases of AML, conferring an adverse prog-
nosis (Stirewalt and Radich, 2003). However, despite the high
frequency of FLT3 expression in ALL and the key role of Flt3 in
early lymphoid development (Sitnicka et al., 2002), including
high-level Flt3 expression in lymphoid-primed MPPs (LMPPs)
with combined lymphoid and myeloid potential (Adolfsson
et al., 2005), FLT3-ITDs are rare in cases of ALL, occurring in
<1% in larger series (Leow et al., 2011).
As is the case for most leukemic mutations, it is unclear
how often FLT3-ITDs are a true initiating event in myeloid
malignancies. Indeed, a number of lines of evidence support the
notion that FLT3-ITDs are often acquired secondarily to an initi-
ating clonogenic event (Gale et al., 2008; Jan et al., 2012),
although when involved in chronic myelomonocytic leukemia
(CMML), they may indeed be the initiating mutation (Lee et al.,
2007). Nevertheless, in line with the normal expression pattern
of Flt3 (Adolfsson et al., 2005), results from studies in patients
are compatible with the notion that FLT3-ITDs occur within the
humanMPPcompartment (Levis et al., 2005) and are an essential
driver mutation within the founding leukemic clone (Ding et al.,
2012; Smith et al., 2012). Thus, even though FLT3-ITDs might
occur secondarily to an initiating clonogenic event in many
cases, these mutations occur in multipotent cells (Levis et al.,
2005) and FLT3-ITD GFR signaling appears to be an essential
requirement for leukemia propagation (Smith et al., 2012). It is
possible, therefore, that FLT3-ITDsmay act to dictate the lineage
fate and phenotype of the resulting leukemia. Compatible with a
role of Flt3-ITD signaling in lineage determination, two different
knockin mouse models of Flt3-ITD have been reported to
develop a myeloproliferative phenotype exclusively (Lee et al.,
2007; Li et al., 2008). However, although it was recently sug-
gested that Flt3-ITDs deplete hematopoietic stem cells (HSCs)
(Chu et al., 2012), the key progenitor population that propagates
FLT3-ITD-induced myeloid disease, as well as the cellular and
molecular bases of their myeloid lineage bias, remains unclear.
Using a mouse knockin model of the Flt3-ITD mutation, we
investigated the cellular and molecular mechanisms by which
constitutive GFR signaling might subvert lineage specification
in MPPs and alter the cell fate of early lymphoid progenitors, in
order to explain the myeloid bias of the resulting leukemias.
RESULTS
Flt3-ITD Collaborates with Runx1 Mutation to Induce
Aggressive AML
To definitively determine whether physiologically expressed
FLT3-ITD impacts the establishment of myeloid versus lymphoid
leukemia development, we crossed Flt3ITD/ITD with Runx1fl/fl
(Growney et al., 2005) andMx1-Cre mice to induce Runx1 dele-
tion in MPPs. Importantly, Runx1 loss-of-function mutation is
associated with both lymphoid and myeloid leukemia (Gross-
mann et al., 2011; Schnittger et al., 2011). Unexpectedly, even
without poly I:C induction, Flt3ITD/ITDRunx1fl/flMx1-Cre+ mice
developed a high-penetrance, short-latency acute leukemia
(Figure 1A) characterized by marked leukocytosis, anemia, and
thrombocytopenia (Figures S1A–S1C) and hepatosplenome-
galy. Peripheral blood (PB) and bone marrow (BM) morphology
resembled AML in all diseased mice (Figures 1B–1D), and
myeloid lineage was confirmed by flow cytometry (Figures 1E
and S1D). Development of ALL was never observed. Leukemias
showed deletion of the Runx1 DNA-binding domain (Figure S1E).
The uniform myeloid-lineage leukemias in Flt3ITD/ITDRunx1fl/fl
Mx1-Cre+ mice demonstrate a key role for Flt3-ITD signaling in
introducing a myeloid-lineage bias during leukemogenesis.
Flt3-ITDs Expand Myeloid-Biased LMPPs
We next investigated the cellular and molecular bases for
FLT3-ITD-induced myeloid bias. As shown previously (LeeCet al., 2007), the multipotent LinSca1+c-Kit+ (LSK) compart-
ment was expanded in Flt3ITD/ITD mice (Figure 2A). We applied
CD150 and CD48 to determine the nature of the expanded cells
within the LSK compartment (Kiel et al., 2005), as Flt3-ITD is
not detectable at the cell surface (Figure S2A). Notably, the
expansion of LSKs was wholly attributable to a marked expan-
sion of LSKCD15048+ MPPs in 8- to 10-week-old Flt3ITD/ITD
mice (Figures 2B and 2C), in line with the recent observation
that Flt3-ITD may suppress the HSC compartment (Chu et al.,
2012). Heterozygous (Flt3ITD/+) mice had an intermediate pheno-
type between Flt3+/+ and Flt3ITD/ITDmice (Figures S2B and S2C).
High-level Flt3 expression in the normal LSK compartment de-
fines LMPPs that lack self-renewal and megakaryocytic (Mk)
and erythroid (E) potential but sustain lymphomyeloid capa-
bility (Adolfsson et al., 2005), a progenitor that is also impli-
cated in human AML (Goardon et al., 2011). Because Flt3high
LMPPs reside almost exclusively in the LSKCD15048+ com-
partment (Figure S2D), we explored whether the expanded
LSKCD15048+ cells in Flt3-ITDmice had LMPP-like character-
istics. As expected for LMPPs (Ma˚nsson et al., 2007), HSC- and
MkE-affiliated gene expression was downregulated in Flt3ITD/ITD
LSKCD15048+ MPPs (Figures 2D, 2E, and S2E), and in line
with the molecular data they possessed little or no Mk potential
in vitro (Figure 2F). In contrast, myeloid-affiliated gene expres-
sion was upregulated in Flt3ITD/ITD LSKCD15048+ cells (Fig-
ure 2G), paralleled by high granulocyte-macrophage (GM)
potential in vitro (Figure 2H). Early lymphoid transcriptional pro-
grams were downregulated in both Flt3ITD/ITD and Flt3ITD/+
LSKCD15048+ MPPs (Figures 2I and 2J), paralleled by severely
reduced B cell potential in vitro (Figure 2K). Importantly, the
lymphoid transcriptional program was already suppressed in
Flt3ITD/ITD LSKCD15048+ MPPs in embryonic day 15 (E15) fetal
liver (FL) (Figure S2F), at which time the phenotype and number
of LSKCD15048+ MPPs were unaffected (Figure S2G). In keep-
ing with this suppression of early lymphoid programs in fetal
MPPs, the number of B220+CD19+ B cells was suppressed in
Flt3-ITD E15 FL (Figure S2H), preceding the emergence of a
myeloproliferative phenotype at this early stage of ontogeny
(Figure S2I). This supports the notion that lymphoid suppression
and myeloid bias in MPPs occurs as a cell-intrinsic and direct
consequence of Flt3-ITD signaling.
Because FLT3-ITDs in humans often occur secondarily to an
initiating clonogenic event (Jan et al., 2012), it is possible that
in such cases it is the other genetic events and not the FLT3-
ITD that influence the leukemic phenotype. In order to address
this issue, we used Vav-Cremediated recombination to examine
the impact of Runx1 loss of function on lineage priming in MPPs
in the absence of Flt3-ITD. The data obtained demonstrate a sig-
nificant upregulation of Il7r andRag1 expression inMPPswith no
significant impact on sIgH expression (Figure S2J). This finding is
in keeping with the high incidence of lymphoid malignancies in
mouse models of Runx1 mutation (Jacob et al., 2010; Kundu
et al., 2005; Putz et al., 2006) and contrasts markedly with the
suppression of lymphoid programs caused by Flt3-ITDs in
MPPs. This supports the notion that it is GFR signaling through
Flt3-ITD that instructs the uniform myeloid phenotype of leuke-
mias resulting from the collaboration between Runx1 deletion
and FLT3-ITD in LMPPs.ell Reports 3, 1766–1776, June 27, 2013 ª2013 The Authors 1767
Figure 1. Mutation of Runx1 in Flt3ITD/ITD Mice Results in High-Penetrance Aggressive Myeloid Leukemia
(A) Leukemia-free survival curves of Flt3ITD/ITDRunx1fl/fl mice stratified according to Mx1Cre genotype (n = 50–68 mice of each genotype).
(B and C) Low-power (203; B) and high-power (1003; C) morphology of typical leukemic cells in Flt3ITD/ITDRunx1fl/flMx1Cre+ mice.
(D) Differential morphology results fromBMofWT (+/+), Flt3ITD/ITDRunx1fl/flMx1Cre, and leukemic Flt3ITD/ITDRunx1fl/flMx1Cre+mice; percentage of total BM cells.
Mean (SEM) values for 4–11 mice of each genotype.
(E) Fluorescence-activated cell sorting (FACS) analysis of PB and BM from an Flt3ITD/ITDRunx1fl/flMx1Cre+ mouse with myeloid leukemia (representative of 19
further analyzed cases).
Error bars represent SEM. See also Figure S1.
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Figure 2. Flt3-ITDs Expand Myeloid-Biased MPPs
(A) Expansion of LSK cells in 8- to 10-week-old Flt3ITD/ITD mice (+/+: n = 27; ITD/ITD: n = 23).
(B) Expression of CD48 and CD150 on BM LSK cells from Flt3+/+ and Flt3ITD/ITD mice.
(C) Expansion of LSKCD48+CD150 MPPs in 8- to 10-week-old Flt3ITD/ITD mice (+/+: n = 27; ITD/ITD: n = 23).
(D) GSEA demonstrating downregulation of E-affiliated genes in Flt3ITD/ITD versus Flt3+/+LSKCD48+150 MPPs (n = 4 of each genotype). FDR, false discovery
rate; NES, normalized enrichment score.
(legend continued on next page)
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Flt3-ITD Suppresses Early T- and B-Lymphoid
Progenitors
Because Flt3-ITD compromised lymphoid-transcriptional prim-
ing in LMPPs, which have been implicated as critical thymus-
seeding progenitors (Luc et al., 2012), we next investigated
whether T lymphopoiesis might be suppressed in Flt3-ITD
mice. Thymic cellularity was found to be progressively reduced,
and the earliest thymic progenitors (double-negative 1 Kit+
[DN1Kit+]) were almost completely lost in Flt3ITD/ITDmice (Figures
3A–3C). Also, subsequent stages of DN2Kit+ andDN3 thymocyte
progenitors were severely reduced (Figures S3A and S3B).
Of relevance, gene and protein expression for the chemokine
receptor Ccr9, which is critical for migration of thymus-seeding
progenitors from the BM to the thymus (Schwarz et al., 2007),
was suppressed in Flt3ITD/ITD LSKCD15048+ MPPs (Figures
3D, S3C, and S3D). Moreover, DN1 cells showed large reduc-
tions in expression of Notch1 and its targets (Hes1 and Hes5;
Figure S3E), which are critical for early T cell development.
Although expression of some early lymphoid genes (Il2ra, Il7r,
and Gata3) was maintained, myeloid genes (Cebpa, Sfpi1,
Csf1r, Csf2r, and Csf3r) were highly upregulated in DN1 thymic
progenitors (Figure S3E). In keeping with this myeloid bias,
Flt3ITD/ITD DN1 progenitors showed low T cell potential in vitro
(Figure 3E).
Previous studies demonstrated a reduction of mature B cells
in Flt3-ITDmice (Lee et al., 2007; Li et al., 2008). We investigated
whether this might reflect Flt3-ITD-induced perturbation at
the earliest B cell commitment stages, and in support of this
found a notable 11-fold expansion of LinCD19CD24
AA4.1+CD43midB220+ pre-pro-B cells in Flt3ITD/ITDmice (Figures
3F and 3G), whereas pro-B cells, the next stage in B cell devel-
opment, were severely reduced (Figures 3H and S3F). Because
pre-pro-B cells are known to sustain low-level myeloid potential
(Rumfelt et al., 2006), we next investigated lymphoid andmyeloid
gene expression in Flt3ITD/ITD pre-pro-B cells. Key early lymphoid
genes (Cd79a, Il7r, sIgh, Ebf1, Pax5, Rag1, and Rag2) were
all suppressed (Figure 3I), whereas myeloid-affiliated genes
(Cebpa, Cebpb, Sfpi1, Csf1r, and Csf2r) were upregulated in
Flt3ITD/ITD pre-pro-B cells (Figure 3J). In agreement with this,
Flt3ITD/ITD pre-pro-B cells had severely reduced B cell potential
(Figure 3K). These findings demonstrate that Flt3-ITDs markedly
impair the earliest stage of both T and B lymphopoiesis and
upregulate myeloid gene expression in the earliest B and T
lymphoid progenitors, in agreement with the notion that myeloid
bias initiates in multipotent LMPPs.(E) Reduced MkE-affiliated gene expression in LSKCD48+150 cells from Flt3+
represent a comparison of Flt3+/+LSK FLT3 cells versus LSKCD48+150 Flt3ITD
Differences among Flt3+/+, Flt3ITD/+, and Flt3ITD/ITD MPPs were not significant.
(F) Single-cell Mk potential of Flt3+/+and Flt3ITD/ITD LSKCD48+150 MPPs in com
(G) GSEA demonstrating upregulation of myeloid affiliated genes in Flt3ITD/ITD ve
(H) Single-cell GM potential of Flt3+/+and Flt3ITD/ITD LSKCD48+150MPPs. Open b
of highly proliferative clones (covering >50% of the well; n = 3 independent expe
(I) GSEA demonstrating downregulation of lymphoid transcriptional program in F
(J) Expression of lymphoid-affiliated genes in LSKCD48+150MPPs from Flt3+/+,
p values indicate comparisons of Flt3+/+ versus Flt3ITD/+ MPPs, and Flt3+/+ versu
(K) B cell potential (B220+CD19+) of Flt3+/+ versus Flt3ITD/ITDBM LSKCD48+150M
replicate wells in each experiment.
Error bars represent SEM. See also Figure S2.
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Upregulation of Pu1
To further explore the mechanistic basis of Flt3-ITD-induced
myeloid bias of early lymphoid progenitors, we examined Pu1
protein expression using a Pu1-YFP reporter line. Whereas in
wild-type (WT) mice Lin cells showed a bimodal distribution
between Pu1low/ and Pu1high cells, almost all Lin cells in
Flt3ITD/ITDmice were Pu1high (Figure 4A). Flt3ITD/ITDmice showed
a modest increase in Pu1 expression in LSKCD15048+ MPPs
(Figure 4B) and markedly enhanced levels of Pu1-YFP in pre-
pro-B cells (Figure 4C). In keeping with the observed increased
expression of Pu1, gene set enrichment analysis (GSEA) demon-
strated upregulation of Pu1 target genes (Steidl et al., 2006)
in Flt3-ITD LSKCD15048+ MPPs (Figure 4D). Furthermore,
GSEA also demonstrated a similar upregulation of Pu1 target
genes in FLT3-ITD mutated ‘‘LMPP-like’’ leukemia stem cells in
human AML (Goardon et al., 2011) in comparison with FLT3-
WT counterparts (Figure S4A).
Because transition from pre-pro-B cells to subsequent stages
of B cell development is associated with downregulation of Pu1
expression (Figure S4B), we attempted to rescue the suppressed
B cell phenotype in Flt3-ITDmice through generation of Flt3ITD/ITD
Pu1+/mice. Notably, whereas Pu1 haploinsufficiency did not in-
crease the number of B cells or their progenitors on a WT back-
ground, it resulted in a 10.3-fold increase in B cells in Flt3ITD/ITD
mice (Figure 4E). Furthermore, Pu1 haploinsufficiency led to a 2-
fold reduction in the expanded pre-pro-B cell population in Flt3-
ITD mice (Figure 4F) together with a 13.5-fold rescue of the sup-
pression of pro-B cells (Figure 4G). Strikingly, in the presence of
Pu1 haploinsufficiency, the expansion ofMPPswas also restored
toWT levels (Figure 4H) together with a significant amelioration of
the myeloproliferative phenotype in Flt3ITD/ITD mice (Figure 4I).
Stat3 is aberrantly activated by Flt3-ITD signaling (Schmidt-
Arras et al., 2009) and Pu1 is a direct target gene of Stat3 (Hegde
et al., 2009). In line with this, Flt3ITD/ITD BM showed aberrant
activation of STAT3 (Figure S4C), and MPPs and pre-pro-B cells
showed significantly increased expression of Stat3 target genes
(Figures 4J–4L). Collectively, these data suggest that Pu1 upre-
gulation is a key mediator of the Flt3-ITD-induced myeloid bias
and progenitor phenotype.
DISCUSSION
In the studies presented here, we explored whether and how
GFR signaling might influence lineage specification in vivo. To/+, Flt3ITD/+, and Flt3ITD/ITD mice relative to Flt3+/+ LSK FLT3 cells; p values
/ITD cells by unpaired t test (n = 6–8 replicates from 2–3 mice per genotype).
parison with Flt3+/+LSKCD48150+ HSCs (n = 3 independent experiments).
rsus Flt3+/+LSKCD48+150 MPPs (n = 4 of each genotype).
ars show the frequency of clones formed, and closed bars show the frequency
riments).
lt3ITD/ITD versus Flt3+/+ LSKCD48+150 MPPs (n = 4 of each genotype).
Flt3ITD/+, and Flt3ITD/ITD mice (n = 6–8 replicates from 2–3 mice per genotype);
s Flt3ITD/ITD MPPs by unpaired t test (p < 0.001 for all analyses).
PPs (10 cells/well). Data are mean (SEM) values of 2–3 experiments, with 9–12
(legend on next page)
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that end, we used a knockin model of Flt3-ITD to investigate
whether oncogenic mutations that result in constitutive GFR
signaling influence the lineage fate of MPPs in vivo.
In order to first establish the physiological relevance of Flt3-
ITD as an AML-inducingmutation, we developed amousemodel
in which Flt3-ITD was coexpressed with an inducible deletion of
the DNA-binding domain of Runx1 (Growney et al., 2005) in
MPPs. Importantly, although Runx1 loss-of-function mutations
are found in patients with both ALL and AML, only the latter is
often found in association with FLT3-ITDs (Grossmann et al.,
2011; Schnittger et al., 2011). Deletion of the DNA-binding
domain of Runx1 during adult murine hematopoiesis results in
mild myeloproliferation (Growney et al., 2005) or lymphoblastic
leukemias/lymphomas (Jacob et al., 2010; Kundu et al., 2005;
Putz et al., 2006). Here, we demonstrate that the combination
of Runx1 mutation with Flt3-ITDs results in aggressive leukemia
with 100% penetrance and a uniform myeloid phenotype. In
addition to demonstrating the functional relevance for FLT3-
ITD-induced AML, this AML model has a number of important
features. First, in contrast to many other mutation collaboration
models, both mutations are targeted to the physiologically rele-
vant endogenous genetic loci. Second, in isolation each muta-
tion results in only a modest phenotype, but in combination a
minor clone of deleted cells rapidly expands and becomes
clonally dominant, paralleling somatic mutations during leuke-
mogenesis. Third, the evolution of leukemia is rapid, supporting
the notion that it occurs without the requirement for additional
genetic events. Finally, the model recapitulates a particularly
poor prognostic form of AML with a major unmet need for novel
therapeutic approaches and thus provides a powerful model for
future studies of the cellular andmolecular mechanistic bases for
collaboration of these mutations in AML.
The most primitive progenitor population that was expanded
by Flt3-ITDs consisted of LMPP-like cells, demonstrating upre-
gulation of the myeloid program, whereas the transcriptional
expression of lymphoid-affiliated genes was markedly reduced
in both heterozygous and homozygous Flt3-ITD mice. This
myeloid transcriptional bias and suppression of lymphoid tran-
scripts was also present during early B and T cell development
and, importantly, was already present in Flt3-ITD FL MPPs, pre-Figure 3. Early T and B Cell Progenitors Are Suppressed and Myeloid
(A) Thymic cellularity of Flt3+/+ and Flt3ITD/ITD mice at 2–3 and 8–10 weeks (n = 7
(B) Representative DN staging of Flt3+/+ and Flt3ITD/ITD thymocytes from 2-week-
(C) Progressive reduction of DN1Kit+ cells in Flt3ITD/ITD thymus.
(D) Expression (SEM) of Ccr9 in LSKCD48+150 BM cells from 8- to 10-week-old
replicates per mouse).
(E) T cell potential on OP9DL1 cells of DN1 cells (10/cells per well) from 2- to 3-wee
mouse). ND, not detected.
(F) Representative staging of early B cell progenitors in Flt3+/+ and Flt3ITD/ITD
CD24AA4.1+CD43mid; percentage of total BM cells.
(G) Increased numbers of pre-pro-B cells in 2- to 3-week-old Flt3ITD/ITD mice (me
(H) Reduced numbers of pro-B cells (LinB220+CD43+CD19+CD24intAA4.1+) in F
(I) Mean (SEM) expression of lymphoid-affiliated genes in pre-pro-B cells from 2- t
mouse).
(J) Mean (SEM) expression of myeloid-affiliated genes in pre-pro-B cells from Flt
(K) In vitro B cell potential (B220+CD19+ cells) of pre-pro-B cells from 2- to 3-week
Error bars represent SEM. See also Figure S3.
1772 Cell Reports 3, 1766–1776, June 27, 2013 ª2013 The Authorsceding the expansion of MPPs and development of a myelopro-
liferative phenotype, supporting the notion that it is a direct
consequence of Flt3-ITD signaling in LMPPs. The severe sup-
pression of the earliest thymic progenitors in Flt3-ITD mice and
concomitant lack of Ccr9 upregulation in LMPPs, which have
been implicated as key thymus-seeding progenitors (Luc et al.,
2012), further suggests that thymic seeding might also be
impaired by Flt3-ITDs. These findings demonstrate that the
myeloid propensity of FLT3-ITDs results from FLT3-ITD intro-
ducing a myeloid bias in multipotent lymphomyeloid progenitors
as well as in the earliest B and T lymphoid progenitors.
Pu1 is a dosage-sensitive regulator of myeloid-lymphoid
cell-fate decisions that promotes myeloid differentiation when
overexpressed (DeKoter and Singh, 2000). Using a Pu1-YFP
reporter, we demonstrated that Flt3-ITDs upregulate Pu1 ex-
pression in MPPs and the earliest B lymphoid progenitors,
paralleled by increased expression of Pu1 target genes in
MPPs. Furthermore, we confirmed the relevance of these
findings for human AML by demonstrating upregulation of Pu1
target genes in FLT3-ITD mutated LMPP-like human AML
stem cells (Goardon et al., 2011). In agreement with a key
mechanistic role for Pu1 overexpression, Flt3-ITD-induced sup-
pression of B cell development, as well as the Flt3-ITD-associ-
ated progenitor phenotype, was partially rescued by Pu1
haploinsufficiency.
Constitutive Flt3-ITD signaling is distinct from WT Flt3
signaling due to abnormal anchoring of FLT3-ITD in the endo-
plasmic reticulum, with markedly reduced surface Flt3 expres-
sion resulting in aberrant Stat3 activation, as confirmed in our
study (Schmidt-Arras et al., 2009). Because Pu1 is a direct target
gene of Stat3 (Hegde et al., 2009) and Stat3 target genes were
upregulated in Flt3-ITD LSKCD15048+ MPPs and pre-pro-B
cells, this provides a putative direct link between aberrant consti-
tutive Flt3-ITD signaling and Pu1 overexpression as a cause of
aberrant myeloid bias.
Several lines of evidence indicate that FLT3-ITDs frequently
arise early in the transformation process in MPPs (Levis et al.,
2005) and as a driver mutation in the founding leukemic clone
(Ding et al., 2012; Smith et al., 2012), and thus may influence
the lineage of resulting leukemias. Together with our findings,Biased in Flt3ITD/ITD Mice
–10 mice of each genotype at each age).
old mice; percentages are relative to total thymocytes.
Flt3+/+ and Flt3ITD/ITD mice (n = 3–4 mice per genotype, 2–3 separately sorted
k-old Flt3+/+ and Flt3ITD/ITDmice (n = 2mice per genotype, 12 replicate wells per
2- to 3-week-old mice. pre-pro-B cells are identified as LinB220+CD19
an [SEM] values for 2- to 3-week-old mice, n = 8–10 of each genotype).
lt3ITD/ITD mice.
o 3-week-old mice (n = 2 mice per genotype, 3 separately sorted replicates per
3ITD/ITD mice.
-old mice (n = 10 cells/well, 2 mice per genotype, 10 replicate wells per mouse).
(legend on next page)
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this is consistent with a model in which LMPPs, which normally
express high levels of FLT3 (Adolfsson et al., 2005), acquire
FLT3-ITD mutations that confer both a strong clonal advantage
and a marked myeloid bias. This results in myeloid expansion
and suppression of early lymphoid development, strongly sup-
porting a fundamental role for FLT3-ITDs in promoting myeloid
lineage leukemia development at the MPP level. Our study
also further highlights LMPPs as a key target population in
AML, as also supported by recent findings in human AML (Goar-
don et al., 2011). Transformation to an aggressive leukemia
exclusively of a myeloid phenotype by introduction of Runx1
mutation demonstrates the functional relevance of this FLT3-
ITD-induced myeloid bias and clonal dominance, providing
insights into the process by which oncogenic mutations might
determine the lineage fate of the resulting leukemias at the pre-
commitment stage. Our findings are also of considerable rele-
vance for normal hematopoiesis, as it remains disputed whether
key cytokine receptor signaling pathways mediate critical in vivo
functions in blood lineage development through purely permis-
sive rather than instructive actions (Enver and Jacobsen,
2009). Thus, although Flt3-ITD elicits aberrant signaling, our
findings clearly provide support for the notion that cytokine re-
ceptors are also capable of eliciting lineage-instructive signaling
in MPPs in vivo.
EXPERIMENTAL PROCEDURES
Animals
All animals used were bred and maintained in accordance with regulations of
the UK Home Office. Details regarding the mouse lines are provided in the
Extended Experimental Procedures.
Patient Samples
BM samples from AML patients were obtained with informed consent and the
approval of Oxford Ethics Committee B (protocols 06/Q1606/110 and 05/
MRE07/74).
Fluorescence-Activated Cell Sorting
Details of the antibody staining panels and protocols are provided in the
Extended Experimental Procedures. Antigens and antibodies used for identi-
fication of specific cell populations are shown in Tables S1 and S2.Figure 4. Involvement of PU1 Upregulation in the Myeloid Bias of Flt3I
(A–C) Representative FACS analysis of PU1-YFP expression in lineage-negative (A
pro-B (C) cells in BM of 2- to 3-month-old Flt3+/+ and Flt3ITD/ITDmice. Also shown
mice of each genotype.
(D) GSEA demonstrating upregulation of Pu1 target genes in LSKCD48+150 MP
(E) Percentage of B220+CD19+ in the BM of 6- to 8-week-old Flt3+/+Pu1+/+, Flt3
genotype; fold difference and p value are for the difference between Flt3ITD/ITDPu
(F) Percentage of pre-pro-B cells in the BM of 6- to 8-week-old Flt3+/+Pu1+/+, F
genotype).
(G) Percentage of pro-B cells in the BM of 6- to 8-week-old Flt3+/+Pu1+/+, Flt
genotype).
(H) Percentage of LSKCD48+150MPPs in the BM of 6- to 8-week-old Flt3+/+Pu1
each genotype).
(I) Percentage of Mac1lowcKitlow myeloid precursor cells in the BM of 6- to 8-wee
(n = 7–9 mice of each genotype).
(J) GSEA demonstrating upregulation of STAT3 target genes in Flt3ITD/ITD versus
(K and L) Expression of Stat3 target genes in Flt3+/+ and Flt3ITD/ITD LSKCD48+150
per mouse). ND, not detected.
Error bars represent SEM. See also Figure S4.
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Cells were lysed in 1%NP40 buffer and analyzed by western blot as previously
described (Pecquet et al., 2010) with antibodies against pStat3 (Cell Signaling)
and beta-actin (Sigma).
In Vitro Evaluation of Lineage Potentials
Evaluation of megakaryocytic, GM, and lymphoid potentials was carried out as
previously described (Ma˚nsson et al., 2007) and detailed in the Extended
Experimental Procedures.
Gene Expression by Dynamic Arrays
Multiplex quantitative PCR was performed as previously described (Kharazi
et al., 2011) and detailed in the Extended Experimental Procedures. Assays
used for dynamic arrays are shown in Table S3.
Microarray Analysis
Analysis by Affymetrix Mouse Genome 430 2.0 Arrays was carried out at the
Stanford Protein and Nucleic Acid Facility as described previously (Ma˚nsson
et al., 2007) and in the Extended Experimental Procedures.
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